Defender Capital's Stance on STAAR Surgical and Alcon Deal

Author: Evelyn Baker Updated: 10-07-2025 12:10 PM

Defender Capital Challenges STAAR Surgical's Sale Proposal

Defender Capital, a prominent shareholder of STAAR Surgical Company (NASDAQ: STAA), has made headlines with its decisive opposition to the proposed acquisition of STAAR by Alcon Inc. (NYSE: ALC). This strategic stance reflects the deep convictions held by Defender Capital, which owns around 1.5% of STAAR's outstanding common stock. The firm believes the proposed sale, priced at $28 per share, drastically undervalues the company.

Concerns Over Valuation

With over a decade of investment experience and significant holdings in STAAR, Defender Capital's executives feel that the proposed selling price does not align with STAAR's true worth. They argue that the offer is even more perplexingat when considering the STAAR Board's previous rejection of an offer from Alcon that stood at $58 per share just sixteen months prior. The stark contrast between these valuations raises serious concerns for stakeholders.

Positive Future Outlook

During a recent statement, Defender Capital emphasized that STAAR Surgical's management has released promising projections about the company's performance. This positive outlook strengthens their argument against the sale. The firm believes that there is ample potential for STAAR to flourish as an independent entity, which they feel warrants a review of the proposed acquisition.

Defender Capital's Commitment to Shareholders

As an SEC-Registered Investment Advisor, Defender Capital manages a diverse portfolio, including retirement and non-retirement accounts, across various client demographics. Their strategy is guided by a research-driven approach, prioritizing long-term investments in U.S. equities. Defender Capital's commitment to STAAR reflects not only their confidence in the company but also their dedication to safeguarding the interests of their investors.

Contacts and Company Insights

Investors seeking more information about Defender Capital or wishing to discuss this viewpoint further can reach out via their contact at ASC Advisors. Taylor Ingraham is available for inquiries, which provides an avenue for clear communication regarding stakeholder concerns and investor strategies.

Defender Capital reiterates its belief in STAAR's robust market position and future potential, highlighting that any premature sale could jeopardize the returns expected by its shareholders. Furthermore, they advocate for a careful assessment from the STAAR Board as the timeline for final decisions continues to approach. Their stance is clear: they will resist any undervalued maneuvering that could diminish the company’s legacy and its promising trajectory.

Frequently Asked Questions

What is Defender Capital's position on STAAR Surgical's acquisition by Alcon?

Defender Capital strongly opposes the acquisition, arguing that the proposed valuation significantly undervalues the company.

How long has Defender Capital been a shareholder of STAAR Surgical?

Defender Capital has been a shareholder of STAAR Surgical for over ten years.

What price was previously offered by Alcon for STAAR Surgical shares?

Alcon had previously offered $58 per share for STAAR Surgical, which was rejected by the STAAR Board.

What does Defender Capital suggest about STAAR's future?

Defender Capital believes that STAAR has a strong future and prospects as a standalone company, supported by positive management projections.

How can shareholders communicate with Defender Capital?

Shareholders can reach out to Taylor Ingraham at ASC Advisors via the provided contact details for further discussions.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.